Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations. (2018)

First Author: Hollis RL

Attributed to: Medical and Regulatory Genomics funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1186/s12885-017-3981-2

PubMed Identifier: 29298688

Publication URI: http://europepmc.org/abstract/MED/29298688

Type: Journal Article/Review

Volume: 18

Parent Publication: BMC cancer

Issue: 1

ISSN: 1471-2407